166results about How to "High drug loading" patented technology

The invention provides a soak solution for a corneal contact lens, a preparation method of the soak solution and the corneal contact lens, and the soak solution is mainly prepared from the following raw materials in percentage by mass: 0.01%-0.15% of litamilast, 0.01%-0.15% of sodium dodecyl benzene sulfonate, 0.01%-0.15% of sodium dodecyl benzene sulfonate and the balance of water. 0.1%-2% of buffer salt; 0.2%-1.2% of sodium chloride; 0-0.5% of sodium thiosulfate; and 97%-99% of purified water. The soak solution for the corneal contact lens prepared by the invention can well interact with water molecules in the corneal contact lens, so that drug molecules in the soak solution are well replaced in the corneal contact lens, and the drug molecules are retained in a gel network of the corneal contact lens; the bioavailability of the medicine is improved while high medicine loading capacity is realized, and the corneal contact lens prepared from the soak solution has the effect of slowly releasing the medicine, directly acts on eyes and can reduce the toxic and side effects of the medicine.

The invention relates to a targeted drug delivery carrier based on mesoporous polydopamine nanoparticles and application thereof.The targeted drug delivery carrier is galactose modified mesoporous dopamine coordinated with manganese ions, lysine is adopted in the carrier synthesis step to provide an alkaline environment needed by dopamine polymerization, the polymerization process is simplified, and the drug delivery efficiency is improved. Meanwhile, lysine can be introduced into the mesoporous polydopamine; and the drug loading capacity of the carrier is improved. The carrier gathers multifunctionality of drug delivery, tumor imaging and treatment, provides a comprehensive new method for tumor treatment, and enhances individuation and precision of treatment.

The invention provides a preparation method and application of magnesium L-threonate, and belongs to the technical field of medicines. The preparation method comprises the following steps: dissolving L-ascorbic acid in water, adding magnesium hydroxide and alkaline magnesium carbonate, stirring, dropwise adding hydrogen peroxide, heating, stirring and reacting, filtering a product, purifying and concentrating by temperature-sensitive molecularly imprinted hydrogel while the product is hot, adding an ethanol water solution into a concentrated solution, standing, crystallizing, filtering, washing and drying to obtain the magnesium L-threonate. And cooling the temperature-sensitive molecularly imprinted hydrogel after adsorption to room temperature, washing and repeatedly using the temperature-sensitive molecularly imprinted hydrogel. The magnesium L-threonate is simple in preparation method, high in purity and high in yield, meanwhile, the slow-release magnesium L-threonate is prepared, and the magnesium L-threonate is low in toxicity, good in biocompatibility, large in drug loading capacity, low in economic cost and good in drug effect and has wide application prospects in preparation of anti-depression drugs.

The invention discloses a curcumin-loaded brain-targeted drug delivery system as well as a preparation method and application thereof. The delivery system comprises a carrier macrophage and a curcumin drug, the curcumin nano-drug is prepared by encapsulating curcumin with a lipoic acid modified cyclodextrin conjugate, then macrophages and the curcumin nano-drug are mixed, and co-incubation is carried out, so that the curcumin nano-drug is constructed. The brain-targeted macrophage drug delivery system loaded with curcumin is a multifunctional composite drug with brain targeting property for treatment of cerebral arterial thrombosis. A brain-targeted macrophage drug delivery system loaded with the curcumin nano-drug gathers in cerebral apoplexy tissues, phenotypic transformation of inflammatory microglial cells is promoted, and a pro-inflammatory microenvironment is improved; the oxidative stress pressure of the stroke part is improved; the two effects promote each other, the stroke microenvironment is improved, the functions of neuronal cells are saved, the synergistic nerve protection effect can be achieved in the aspect of treating ischemic cerebral apoplexy, and potential safety hazards are reduced.

The invention provides a large polyester bio-fiber containing rose active ingredients and a preparation method of the large polyester bio-fiber. The large polyester bio-fiber comprises the following raw materials in parts by weight: 10-12 parts of polyester chips and 2-3 parts of rose extract microcapsules, the preparation method of the rose extract microcapsule comprises the following steps: adding tannic acid into a sodium alginate aqueous solution, stirring and mixing to obtain a solution A, adding nano-hydroxyapatite, a calcium chloride / glutaraldehyde composite cross-linking agent, a rose extract and lauryl sodium sulfate into a chitosan acetic acid aqueous solution, stirring and mixing to obtain a solution B, and uniformly stirring to obtain the rose extract microcapsule. And mixing and stirring the solution A and the solution B to obtain the rose extract microcapsule. According to the polyester large biological fiber containing the rose active component and the preparation method of the polyester large biological fiber, the rose active component is effectively and uniformly introduced into the polyester fiber, meanwhile, the original physical performance of the fiber is kept, the stability of the active component is further kept, the slow release time is prolonged, and the polyester large biological fiber is endowed with more health functions.

The invention provides a camptothecin prodrug. The camptothecin prodrug provided by the invention has higher drug retention in the liposome and better stability, and the prodrug liposome can maintain long-time plasma concentration in plasma. In-vitro characterization of the camptothecin prodrug liposome shows that the camptothecin prodrug liposome has higher encapsulation efficiency, drug loading capacity and stability, and can achieve a slow release effect in plasma; the experimental result on the cellular level shows that the compound has higher cellular uptake rate; in-vivo experiments prove that the compound has a better tumor accumulation effect and antitumor activity, can tolerate a higher dosage, and has higher biological safety.

The invention discloses epigallocatechin gallate starch nanoparticles as well as a preparation method and application thereof, and belongs to the technical field of medicinal chemistry. According to the method, high-proportion branched-chain cassava starch is used as a raw material, ultrasonic microwave assistance is adopted, in the nanometer starch alcohol precipitation process, epigallocatechin gallate is synchronously packaged to form nanometer-level epigallocatechin gallate starch nanometer particles, and embedding of epigallocatechin gallate is completed. The embedding rate of the epigallocatechin gallate starch nanoparticles can reach 50.20%, the drug loading capacity can reach 311mg / g, the drug slow release performance is obvious in the process of simulating gastrointestinal digestion, the sustained release time can be 20 hours, the drug release capacity can reach 72.33% and 90.10% respectively, and the preparation process is simple, easy to operate, low in preparation cost and suitable for large-scale production and application.

The invention relates to a water-in-oil nanoemulsion with high drug loading capacity as well as a preparation method and application of the water-in-oil nanoemulsion. The water-in-oil nanoemulsion is prepared by dropwise adding a water-phase solution containing tocoxolam into an oil-phase solution, the water-phase solution is prepared from tocopherol, a cosurfactant, a hydrophilic active matter, a preservative and water; the oil phase solution is composed of liquid grease and a surfactant; the water-in-oil nanoemulsion is prepared from the following components in percentage by mass: 50 to 64 percent of liquid grease, 10 to 17 percent of surfactant, 5 to 8 percent of tocoxolam, 5 to 12 percent of surfactant, 0.1 to 6 percent of hydrophilic active matter, 0.2 to 0.6 percent of preservative and 8 to 15 percent of water. The water-in-oil nanoemulsion has the advantages of high drug loading capacity, good skin permeability, high retention volume in skin cells, high bioavailability, good stability, high safety and the like, and can be used in pure oil cosmetics.

The invention provides a silibinin mixed micelle injection as well as a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations. The cholate / lecithin mixed micelle system constructed by adopting specific cholic acid and phospholipid has good stability, can be well compatible with the silibinin so as to well encapsulate the silibinin, can obviously improve the solubility of the silibinin, has higher safety under the condition of ensuring the stability of the silibinin, and can be used for preparing a medicine for treating the silibinin. Therefore, the bioavailability of the silibinin is greatly improved. According to the invention, a shearing dispersion method is adopted to prepare the mixed micelles, and the mixed micelles with high drug loading capacity, clarification and good stability for silibinin are formed by destroying and shearing the raw and auxiliary materials in a molecular level, so that the mixed micelles have better physical and chemical stability, the drug quality is easier to control, the process is more simplified, the clinical medication is safer and the cost is lower; and the accessibility of the medicine is improved.

The invention discloses an adriamycin-tetravalent platinum drug-norcantharidin three-drug combined nano-drug as well as a preparation method and application thereof, and belongs to the technical field of medical materials. A tetravalent platinum drug modified by demethylated cantharidin and adriamycin are used as raw materials, a novel nano-drug is constructed through Cu < 2 + > coordination, and then the nano-drug combining adriamycin, the tetravalent platinum drug and demethylated cantharidin is prepared by polymerizing polydopamine with a mild photo-thermal effect. The polymer has the capacity of controllably releasing drugs under acidity and reduction, can realize photo-thermal conversion under laser irradiation to generate a mild photo-thermal effect, has a better tumor cell killing effect, has the capacity of consuming glutathione and generating hydroxyl radicals, can enter cancer cells in an endocytosis mode and release DOX, and can be used for killing tumor cells. And a new thought is provided for multi-drug combination and chemotherapy-chemokinetics therapy-photothermal therapy multi-mode combined therapy.

The invention discloses a ferroptosis-inducing targeted mPDA / MSNs nano-drug delivery carrier as well as a preparation method and application thereof, and relates to the technical field of preparation of targeted nano-delivery carriers. The preparation method comprises the following steps: firstly, connecting and modifying-NH2 to the surfaces of MSNs to obtain amino modified MSNs-NH2; the preparation method comprises the following steps: coating with mPDA to obtain mPDA / MSNs-NH2, and reacting with ferrous lactate to obtain Fe < 2 + >-mPDA / MSNs-NH2; the final carrier RGD-Fe2 +-mPDA / MSNs-NH2 is prepared by coupling an RGD targeting peptide, the particle size is uniform, the physicochemical property is stable, the ATRA and DOX encapsulation efficiency and the drug loading capacity are high, the drug can be responsively released in a simulated tumor microenvironment, a drug-loaded sample RFP / MN atD / A can deliver a drug into tumor cells in a targeting manner, ferroptosis can be rapidly induced, and the tumor cells can be effectively killed through synergistic chemotherapy.

The invention provides a pramipexole oral soluble film composition as well as a preparation method and application thereof. The invention provides a pramipexole oral soluble film composition. The pramipexole oral soluble film composition comprises an active medicine, a film-forming material, a plasticizer and a flavoring agent, the active drug is a hydrochloride of S-2-amino-4, 5, 6, 7-tetrahydro-6-(propylamino)-benzothiazole as shown in a formula I and / or other pharmaceutically acceptable salt forms of the hydrochloride of S-2-amino-4, 5, 6, 7-tetrahydro-6-(propylamino)-benzothiazole as shown in the formula I. The pramipexole oral soluble film composition has the advantages that the pramipexole oral soluble film composition is thin in thickness, fast in disintegration, free of grit feeling after being dissolved in the oral cavity, capable of improving the taste of a medicine and improving the compliance of a patient, capable of being instantly dissolved in the oral cavity without drinking water, fast in oral absorption speed, uniform in film appearance, high in tensile capacity, good in flexibility and long in service life. Meanwhile, the raw materials are easy to obtain, the process is simple, the operation is simple and convenient, the drug loading capacity is high, the drug content uniformity is good, and the preparation method is suitable for industrial production. # imgabs0 #

The invention discloses a transsclera continuous drug delivery device for eye disease treatment and a preparation method thereof. The device comprises an arc body, a wing-shaped fixing plate and a fixing band. A groove is formed in the bottom surface of the arc body; the two wing-shaped fixing plates are symmetrically arranged on the two sides of the arc body. The two wing-shaped fixing plates are respectively accommodated under the abdomen of the external rectus and under the abdomen of the lower rectus; the fixing belts are fixedly connected to the bottom face of the arc body, and gaps are formed between the fixing belts and the inner wall of the groove and used for storing medicine films; the ends, away from the arc body, of the two-wing-shaped fixing plates are spaced, and the arc body and the two-wing-shaped fixing plates are integrally in a C shape. The eye drops can be well attached to eyeballs, compression on the eyeballs is reduced, free rotation of the eyeballs is not affected, wearing comfort and medicine bioavailability are improved, medicine components are prevented from leaking to the keratoconjunctival surface and fascia tissue, medicine is prevented from going into blood pressure circulation through conjunctival blood vessels and lymphatic vessels, and the risk of side effects of the whole body is reduced; and toxicity and adverse reactions are reduced.

The invention relates to the technical field of sodium sarcosine, in particular to slow-release sodium sarcosine and a preparation method thereof. The slow-release sodium sarcosine is prepared from the following raw materials in parts by weight: 70 to 80 parts of sodium sarcosine aqueous solution, 5 to 10 parts of acrylic acid, 5 to 10 parts of acrylamide, 3 to 5 parts of hydrotropy monomer A, 0.5 to 1 part of hydrotropy monomer B, 0.05 to 0.15 part of cross-linking agent and 0.05 to 0.15 part of initiator, and the hydrotropy monomer B is a mixture of diallyl dimethyl ammonium chloride and methacryloyloxyethyl trimethyl ammonium chloride. The sustained-release sodium sarcosinate disclosed by the invention has relatively high drug loading capacity and encapsulation efficiency, does not generate a burst release phenomenon, and can act for a relatively long time in vivo, so that the benefits of the sustained-release sodium sarcosinate are better exerted, the intake frequency is reduced, and the sustained-release sodium sarcosinate has a wide application prospect.

The invention discloses an ultrasonic activation type carrier-free nano-drug as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The nano-drug is formed by self-assembly of a sound-sensitive agent and a chemotherapy prodrug, the sound-sensitive agent is an organic small molecule capable of generating ROS through ultrasonic irradiation, and the chemotherapy prodrug is an ROS response type SN38 prodrug. Only after the carrier-free nano-drug provided by the invention is subjected to ultrasonic irradiation, the sound-sensitive agent can generate active oxygen, further activate the chemotherapeutic prodrug and release the active substance of the chemotherapeutic drug to induce tumor cell apoptosis, the tumor treatment effect is improved in an ultrasonic triggering manner, and toxic and side effects caused by non-specific distribution of the chemotherapeutic drug are avoided. The preparation method disclosed by the invention is simple and mild in reaction condition, and has great potential in the fields of preparation and application of tumor drugs.

The invention discloses a ternary carrier-free nanoparticle as well as a preparation method and application thereof. The ternary carrier-free nanoparticles comprise nanoparticles which are formed by the chlorine e6, the lonidamine and the RG108 through an intermolecular interaction force. The nanoparticles can improve effective absorption and accumulation of drugs in tumors, can induce tumor specific pyroptosis and immunogenic effect under laser irradiation, and can promote maturation of antigen presenting cells and recruitment and activation of cytotoxic T lymphocytes, thereby starting adaptive anti-tumor immunity.

The invention belongs to the technical field of anti-cancer drugs, and particularly relates to a nano-drug, a preparation method and application thereof, and a chemotherapy-photodynamic combined diagnosis and treatment reagent. The nano-drug provided by the invention comprises a vitamin E polyethylene glycol succinate nano-micelle, and a lauric acid modified tetravalent platinum prodrug, a hydrophobic photosensitizer and an emulsifier which are coated in the vitamin E polyethylene glycol succinate nano-micelle. According to the invention, co-transportation of the cis-platinum prodrug and the photosensitizer can be realized; after the nano-drug provided by the invention is passively transported into tumor cells in a targeted manner through an EPR effect, the hydrophobic photosensitizer can increase the generation of singlet oxygen under the irradiation of red light and cooperates with a chemotherapy drug (tetravalent platinum) to act together, chemotherapy and photodynamic therapy are combined, drug resistance can be overcome, and a good treatment effect is achieved; in the treatment process, the dosage of chemotherapeutic drugs is remarkably reduced, and side effects are greatly reduced.

The application discloses a sensitized ferroptosis lipid nano regulator and a preparation method and application thereof, and belongs to the technical field of new adjuvants and new dosage forms of drug preparation combined treatment. The lipid nano regulator is co-assembled by a GPX4 inhibitor and a FASN inhibitor through intermolecular forces, and is modified with an oxidation-reduction sensitive PEG modifier, a molar ratio of the GPX4 inhibitor and the FASN inhibitor is 10:1-1:10, a mass ratio of the sum of the GPX4 inhibitor and the FASN inhibitor to the PEG modifier is 10:90-90:10, and the intermolecular forces include pi-pi stacking force, hydrophobic force and hydrogen bond. The co-assembled nano preparation provides a new strategy and more choices for the development of drug delivery, and meets the urgent needs of high-efficiency and diverse ferroptosis treatment strategies in preparations in the clinic.

The invention discloses nano-particles containing biological enzyme as well as a preparation method and application of the nano-particles. The double-drug nano-particle provided by the invention is prepared by taking a nano composite material Cu / ZIF-8 obtained by modifying a ZIF-8 carrier with a copper base as a carrier, wrapping PPE in the carrier, adsorbing a small molecule drug CB-839 outside to form a nano-drug, and modifying the nano-drug with hyaluronic acid. The double-drug nanoparticle improves the properties of free PPE and CB-839, improves the stability, prolongs the tumor residence time and enhances the curative effect; and PPE and CB-839 can be released under low pH response of lysosome in cells, so that high-efficiency and low-toxicity treatment of tumors is realized. The double-drug nanoparticle can achieve a synergistic anti-tumor effect that 1 + 1 is greater than 2, and has a good application prospect in preparation of anti-tumor drugs.

This invention discloses a Tibetan bath composition compound and its preparation method, relating to the field of daily chemical products technology. The Tibetan bath composition compound consists of a ternary complex of scutellaria baicalensis hydroxypropyl-β-cyclodextrin nanoshell powder, Bacillus subtilis, Tibetan medicine composition, starch, anhydrous citric acid, sodium bicarbonate, calcium citrate, crospovidone, and magnesium stearate. Bacillus subtilis is used to ferment the ternary complex of scutellaria baicalensis hydroxypropyl-β-cyclodextrin nanoshell powder to obtain a fermentation-modified porous carrier, which is then loaded with the Tibetan medicine composition to form a Tibetan medicine inclusion powder. This not only achieves efficient drug delivery through a triple mechanism of biomodification, metabolite synergy, and structural optimization, but also forms a quaternary system with Terminalia chebula. The effervescent effect also enhances the penetration of Tibetan medicine components, which is beneficial for better exerting the antibacterial and anti-inflammatory effects of active substances, and significantly improving fungal infections and eczema-related skin problems.

The invention provides a prodrug molecule based on a zwitterionic polyamide-amine dendrimer, a nano drug-loaded micelle as well as a preparation method and application of the prodrug molecule and the nano drug-loaded micelle. The preparation method of the nano drug-loaded micelle comprises the following steps: after PAMAM is modified by maleic anhydride, thiolated paclitaxel, c (RGDfC) and thiolated histidine are grafted on PAMAM through sulfydryl alkenyl reaction, and hydrophobic anti-cancer drugs are entrapped by utilizing the self-assembly characteristic of PAMAM to form the nano drug-loaded micelle. The nano drug-loaded micelle has the advantages of high drug loading capacity, small toxic and side effects, uniform particle size distribution, good stability, capability of enhancing the bioavailability of hydrophobic drugs and the like, has pH responsiveness, and can realize targeted release of the drugs at tumor parts, so that the tumor inhibition effect is enhanced.

The utility model provides a spherical tablet, and belongs to the field of pharmaceutical preparations. The spherical tablet comprises an upper hemisphere, a lower hemisphere and a middle belt, and the middle belt is located in the middle of the spherical tablet and is in a belt shape with the same thickness. The upper hemisphere and the lower hemisphere are located on the two end faces of the middle belt, and the two hemispheres are the same in size and shape. The diameter of the middle zone is larger than the diameter of the hemisphere, the diameter of the hemisphere of an upper stamping die and the diameter of the hemisphere of a lower stamping die of a tablet pressing die adopted when the spherical tablet is pressed ranges from 6.5 mm to 10 mm, and the ratio of the arc depth to the diameter of the hemisphere is (0.2-0.4): 1. The spherical tablet is small in size, easy to swallow, high in drug loading capacity and less in taking quantity; and the tablet has the advantages of good compressibility, good hardness, strong shock resistance and wear resistance, small tablet weight difference, facilitation of later coating and other operations, and good uniformity and reproducibility.

The present invention relates to a bioactive conjugate, a preparation method therefor, and use thereof. In particular, the present invention relates to a novel type of bioactive molecular conjugates obtained by improving the coupling of a drug to a targeted moiety in ADC or SMDC, a preparation method therefor, and use thereof in the preparation of drugs for treating diseases associated with abnormal cellular activity.

The invention discloses a method for preparing a multilayer oral film, comprising the following steps: preparation of a basement membrane liquid; preparation of a sandwich membrane liquid; preparation of a covering membrane liquid; storing the prepared basement membrane liquid in a plastic box of a casting device, adjusting the wet film thickness by a thickness regulator on the plastic box, and combining the traction of a conveyor belt to make the film liquid in the plastic box uniformly cast, and obtaining a basement membrane after drying in a drying area; flowing the prepared sandwich membrane liquid into a sandwich plastic box after passing through a twin-screw extruder, and uniformly flowing to the top of the basement membrane after controlling the required thickness, and forming the sandwich membrane after drying in a drying area; using a spraying device to evenly spray the prepared covering membrane liquid on the top of the sandwich membrane, and obtaining a multilayer oral film with a three-layer structure after drying in a drying area; cutting the obtained three-layer film into a certain size, sealing and packaging, and irradiating and sterilizing to obtain a finished product. The multilayer oral film obtained by the invention has a large drug dosage, and the film quality is less affected by the ambient temperature and humidity.

The invention discloses a preparation method of a self-oxygen-supply composite nano-carrier applicable to cardiovascular diseases such as myocardial infarction, which comprises the following steps: slowly dripping a potassium permanganate solution into an INN (at) Alb nano-system to promote MnO2 to deposit on the surface of the INN (at) Alb nano-system to prepare a double-layer nano-shell (MnO2 (at) INN (at) Alb), and modifying PEG-2000 on the surface of the double-layer nano-shell to obtain the self-oxygen-supply composite nano-carrier. The obtained self-oxygen-supply composite nano-carrier MnO2 (at) INN (at) Alb can utilize MnO2 to catalyze H2O2 in a myocardial infarction region so as to slowly generate oxygen and reverse a local hypoxic microenvironment of the infarction region, meanwhile, a main drug glibenclamide is slowly released, and the purposes of reducing oxidative stress of myocardial cells, reducing the cell death rate, improving myocarditis and fibrosis and finally improving the heart function are achieved. The pharmaceutical composition can be applied to treatment of cardiovascular diseases such as myocardial infarction, and a new treatment thought is provided for patients with cardiovascular diseases.

The preparation method comprises the following steps: extruding an astaxanthin raw material medicine, copovidone VA64, glucose and other auxiliary materials in a specific proportion in a double-screw hot melt extruder to obtain an astaxanthin nano dispersion so as to enhance the water dispersibility and solubility of the astaxanthin nano dispersion; suspending the astaxanthin nano dispersion in a gelatin solution, and then sequentially carrying out high-speed homogenization and spray drying to obtain astaxanthin microcapsules; according to the preparation method disclosed by the invention, the solid astaxanthin is directly embedded by combining hot-melt extrusion and spray drying, so that the drug loading capacity of the microcapsule is greatly increased, and the solubility and the stability of the astaxanthin are enhanced.

The invention discloses a nasal cavity coated drug-loaded stent and a preparation method thereof, and relates to the technical field of nasal cavity stents.The coated drug-loaded stent comprises a coated drug-loaded stent body and a drug coating covering the surface of the coated stent body, and the drug coating comprises a therapeutic drug and a carrier thereof; the carrier comprises a first polymer and a second polymer which have different drug loading functions; and a tissue regeneration guide layer can also be arranged on the medicine coating. The coated drug-loaded stent provided by the invention not only has a large wound surface contact area, but also can effectively regulate and control the drug release period, so that the drug release during the wound surface repair period is more stable, long-acting and controllable, thereby meeting the needs of nasal cavity wound surface repair.

The present application relates to the technical field of pesticides, and discloses a phase change eutectic carrier embedded with a photothermal agent as well as a preparation method and application thereof.The phase change eutectic carrier embedded with the photothermal agent mainly comprises a photothermal agent, a fatty acid, an organic solvent and water.The preparation process of the preparation is simple, the conditions are mild, a large number of additives are not needed, and the preparation can be quantitatively prepared.The dispersion and utilization rate of the bactericide can be improved through eutectic, and the effectiveness of the bactericide can be improved.The preparation is suitable for various application modes such as seed coating and soil treatment, can play various synergistic functions such as temperature response release, prolonging drug retention time, enhancing adhesion and permeability on the surface of pathogenic bacteria, and is a kind of green and efficient bactericide dosage form, which has a wide application prospect in green and intelligent agriculture.

The application discloses a solid dispersion of olaparib and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The solid dispersion of olaparib adopts polyvinyl alcohol or polyvinyl alcohol and a plasticizer or polyvinyl alcohol and copolymerized povidone or polyvinyl alcohol, copolymerized povidone and an anti-sticking agent as a matrix polymer carrier, can effectively protect the olaparib raw material, reduce the degradation, and improve the drug loading of the solid dispersion. The solid dispersion of olaparib has small hygroscopicity, reduces the requirement of the environment humidity during the storage of the intermediate product of the olaparib preparation, reduces the energy consumption during the preparation process, and significantly improves the stability and effectiveness of the preparation.

The invention belongs to the technical field of ultrasonic imaging agents, and particularly relates to an ultrasonic contrast agent with low side effects, a preparation method and application. The ultrasonic contrast agent with low side effect provided by the invention is prepared from perfluorooctane, phospholipid, cholesterol, 0 cocamidopropyl amine oxide and dithiothreitol. Experimental data show that after being injected with the ultrasonic contrast agent, rats do not die and basically do not have toxic or side effect symptoms, after anatomy, visceral organs do not have obvious pathological changes, and the acute toxicity of the ultrasonic contrast agent is low.